Chronic granulomatous disease: Difference between revisions

From IDWiki
()
m (Text replacement - " species]]" to "]]")
 
(One intermediate revision by the same user not shown)
Line 11: Line 11:
   
 
*Recurrent infections
 
*Recurrent infections
**Catalase-positive organisms, including [[Staphylococcus aureus]], [[Burkholderia cepacia]], [[Serratia marcescens]], [[Nocardia species]], and [[Aspergillus species]]
+
**Catalase-positive organisms, including [[Staphylococcus aureus]], [[Burkholderia cepacia]], [[Serratia marcescens]], [[Nocardia]], and [[Aspergillus]]
 
**CGD is the highest-risk group for [[invasive aspergillosis]]
 
**CGD is the highest-risk group for [[invasive aspergillosis]]
 
*Granuloma formation, often in the GI and GU tracts and may precede other clinical symptoms
 
*Granuloma formation, often in the GI and GU tracts and may precede other clinical symptoms
Line 28: Line 28:
 
==Diagnosis==
 
==Diagnosis==
   
*The diagnosis is confirmed with the dihyohodamine-123 (DHR-123) test
+
*The diagnosis is confirmed with the dihydrohodamine-123 (DHR-123) test
   
 
==Management==
 
==Management==

Latest revision as of 12:56, 2 February 2022

Background

Pathophysiology

  • Defect in NADPH oxidase
  • Therefore unable to generate superoxide radicals required by phagocytes to kill pathogens

Clinical Manifestations

Differential Diagnosis

Diagnosis

  • The diagnosis is confirmed with the dihydrohodamine-123 (DHR-123) test

Management

Further Reading

  • Considerations in the Diagnosis of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc. 2018;7(S1):S6-S11. doi: 10.1093/jpids/piy007